Notice of Refund | Jul 20, 2018 | PAPER | BOARD |
Motion For Refund Of Post-Institution Fee | Jul 2, 2018 | PAPER | PETITIONER |
Denying Institution of Inter Partes Review
35 U.S.C. sec 314(a) and 37 C.F.R. sec 42.108(c) | May 31, 2018 | PAPER | BOARD |
Ex 2002 Jones 1976 | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2007 Kresina | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2008 Sternberg | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2009 Merrill 2010 | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Patent Owners' Exhibit List | Mar 7, 2018 | PAPER | PATENT OWNER |
Ex 2001 US Patent No. 8,664,231 | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2003 Gans 1996 | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2004 Multani 1998 | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2005 US Patent No. 5,484,892 | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Ex 2006 '612 IPR Petition | Mar 7, 2018 | EXHIBIT | PATENT OWNER |
Patent Owners' Preliminary Response | Mar 7, 2018 | PAPER | PATENT OWNER |
Petitioner's Updated Mandatory Notice | Jan 31, 2018 | PAPER | PETITIONER |
Patent Owners' Updated Mandatory Notice | Dec 27, 2017 | PAPER | PATENT OWNER |
NOTICE OF FILING DATE ACCORDED TO PETITION
AND
TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE | Dec 7, 2017 | PAPER | BOARD |
Power of Attorney-Biogen | Nov 17, 2017 | PAPER | PATENT OWNER |
Power of Attorney-Genentech | Nov 17, 2017 | PAPER | PATENT OWNER |
Mandatory Notice | Nov 17, 2017 | PAPER | PATENT OWNER |
Ex. 1003 - Owen Chan and Mark J. Shlomchik, "A New Role for B Cells in Systemic Autoimmunity: B Cells Promote Spontaneous T Cell Activation in MRL-lpr/lpr Mice," J. Immunology, 160:51-59 (1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1005 - Danning et al., "Vasculitis Associated with Primary Rheumatologic Diseases," Current Opinion in Rheumatology, 10(1):58-65 (1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1006 - Rituxan (rituximab) labeling (Nov. 1997) ("FDA label") | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1001 - U.S. Patent No. 8,545,843 B2 , Curd et al. | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1004 - Belmont et al., "Pathology and Pathogenesis of Vascular Injury in Systemic Lupus Erythematosus," Arthritis & Rheumatism, 39(1):9-22 (1996) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1007 - George et al., "Infections and Wegener¿¿¿s Granulomatosis-A Cause and Effect Relationship?" Quarterly J. Med., 90:367-373 (1997) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1008 - Mathieson et al., "T and B Cell Responses to Neutrophil Cytoplasmic Antigens in Systemic Vasculitis," Clinical Immunology & Immunopathology, 63(2): 135-141 (1992) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1009 - Niels Rasmussen and Jorgen Petersen, "Cellular Immune Responses and Pathogenesis in c-ANCA Positive Vasculitides,' J. Autoimmunity, 6(2): 227-236 (1993) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Excerpts from Vols. 1 & 2 Textbook of Rheumatology 5th Ed. (Kelley et al., eds) (1997) ("Kelley Textbook") - Part 2 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Excerpts from Vols. 1 & 2 Textbook of Rheumatology 5th Ed. (Kelley et al., eds) (1997) ("Kelley Textbook") - Part 6 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1011 - David G. Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195 (1997) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1013 - Specks et al., "Response of Wegener¿¿¿s Granulomatosis to Anti-CD20 Chimeric Monoclonal Antibody Therapy," Arthritis & Rheumatism, 44(12): 2836-2840 (2001) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Excerpts from Vols. 1 & 2 Textbook of Rheumatology 5th Ed. (Kelley et al., eds) (1997) ("Kelley Textbook") - Part 1 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Excerpts from Vols. 1 & 2 Textbook of Rheumatology 5th Ed. (Kelley et al., eds) (1997) ("Kelley Textbook") - Part 3 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Excerpts from Vols. 1 & 2 Textbook of Rheumatology 5th Ed. (Kelley et al., eds) (1997) ("Kelley Textbook") - Part 4 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1010 - Excerpts from Vols. 1 & 2 Textbook of Rheumatology 5th Ed. (Kelley et al., eds) (1997) ("Kelley Textbook") - Part 5 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1012 - Rituxan Full Prescribing Information, Genentech Wayback Machine Website. | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1015 - Press Release, National Institute of Allergy and Infectious Diseases (NIAID), "After 40 Years, NIH-Supported Researchers Identify Possible New Treatment for Severe Vasculitis,"(July 14, 2010) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1017 - Gary S. Hoffman and Ulrich Specks, "Antineutrophil Cytoplasmic Antibodies," Arthritis & Rheumatism, 41(9): 1521-1537 (1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1018 - CGM Kallenberg and P Heeringa, "Pathogenesis of Vasculitis," Lupus, 7:280-284 (1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1020 - Takeuchi et al., "Upregulated Expression and Function of Integrin Adhesive Receptors in Systemic Lupus Erythematosus Patients with Vasculitis,¿¿¿"J. Clinical Invest., 92:3008-3016 (1993) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1021 - Cupps et al., "Suppression of Human B Lymphocyte Function by Cyclophosphamide," J. Immunology, 128(6):2453-2457 (1982) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1023 - Theoharides et al., "7 Control of Pain and Inflammation," in Essential of Pharmacology 2d ed. (Theoharis C. Theoharides, ed.) 217-258 (1996) ("Massarotti I") | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1024 - Tanya Doan and Elena Massarotti, "Rituximab," Drugs of Today, 41(12):785-797 (2005) ("Massarotti II") | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - Declaration of Scott Bennett, Ph.D. Part 1 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - Declaration of Scott Bennett, Ph.D. Part 4 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1014 - Stone et al., "Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis," N.E. J. Med., 363(3):221-232 (2010) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1016 - Drenkard et al., "Vasculitis in Systemic Lupus Erythematosus," Lupus, 6:235-242 (1997) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1019 - Roark et al., "Breakdown of B Cell Tolerance in a Mouse Model of Systemic Lupus Erythematosus," J. Experimental Medicine, 181:1157-1167 (1995) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1022 - Andrassy et al., "Wegener's Granulomatosis with Renal Involvement: Patient Survival and Correlations Between Initial Renal Function, Renal Histology, Therapy and Renal Outcome," Clinical Nephrology, 35(4):139-147 (1991) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - Declaration of Scott Bennett, Ph.D. Part 2 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - Declaration of Scott Bennett, Ph.D. Part 5 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1025 - Declaration of Scott Bennett, Ph.D. Part 3 | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1030 - U.S. Application No. 12/886,171, Notice of Allowability (dated May 24, 2013) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1032 - Maloney et al., "DEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," J. Clinical Oncology, 15(10):3266-3274 (1997) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1033 - Darrell R. Anderson, U.S. Patent NO. 5,736,137 (issued April 7, 1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1035 Physicians' Desk Reference (53rd ed. 1999) (excerpted), "Rituxan (Rituximab)" ("PDR label") | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1037 - Remicade (infliximab) labeling (August 1998) ("Remicade" label") | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1039 - Charles Marwick, "Monoclonal Antibody to Treat Lymphoma," J. Am. Med. Ass'n, 278(8):616, 618 (August 27, 1997) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1026 - U.S. Application No. 12/886,171, Amendment in Response to Non-Final Action (dated Apr. 11, 2011) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1027 - U.S. Application No. 12/886,171, Non-Final Office Action (dated Mar. 20, 2012) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1028 - U.S. Application No. 12/886,171, Amendment in Response to Final Action (dated Oct. 29, 2012) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1029 - U.S. Application No. 12/886,171 Amendment to Accompany RCE (dated Nov. 20, 2012) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1031 - E. William St. Clair "Chapter 10: Vasculitis," in Treatment of the Rheumatic Diseases: Companion to the Textbook of Rheumatology (Michael H. Weisman & Michael E. Weinblatt eds.) 137-157 (1995) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1034 - Fauci et al., "Effect of Cyclophosphamide upon the Immune Response in Wegener's Granulomatosis," N.E. J. Med., 285(27):1493-1496 (1971) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1036 - Maini et al., "Therapeutic Efficacy of Multiple Intravenous Infusions of Anti-Tumor Necrosis Factor Monoclonal Antibody Combined with Low-Dose Weekly Methotrexate in Rheumatoid Arthritis," Arthritis & Rheumatism, 41(9):1552-1563 (1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1038 - Gail A. Leget and Myron S. Czuczman "Use of Rituximab, the New FDA-Approved Antibody," Current Opinion in Oncology, 10:548-551 (1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1040 - Sean Henahan, "Anti-CD20 Antibodies Combining Well in Lymphoma Patients," Inpharma, 1136:9 (May 1998) | Nov 2, 2017 | EXHIBIT | PETITIONER |
Ex. 1002 - Declaration of Elena M. Massarotti, M.D. | Nov 2, 2017 | EXHIBIT | PETITIONER |
PETITION FOR INTER PARTES REVIEW '843 | Nov 2, 2017 | PAPER | PETITIONER |
Petitioner's Power of Attorney | Nov 2, 2017 | PAPER | PETITIONER |